Statin use, Candidate Mevalonate Pathway Biomarkers, and Colon Cancer Survival in a Population-Based Cohort Study

Gray, Ronan T.; Loughrey, Maurice B.; Bankhead, Peter; Cardwell, Chris R; McQuaid, Stephen; O'Neill, Raymond; Arthur, Kenneth; Bingham, Victoria; McGready, Claire; Gavin, Anna; James, Jacqueline; Hamilton, Peter; Salto–Tellez, Manuel; Murray, Liam; Coleman, Helen

doi:10.1016/s0016-5085(17)33466-2

Cited by 16 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, six studies involving 86 622 patients reported survival outcomes for patients of pre‐diagnostic statin uses, while 11 studies involving 44 322 patients investigated survival outcomes related to post‐diagnostic statin uses . Eight studies were conducted in Europe (United Kingdom, Denmark, Netherland, Germany), four in North America, and two in Asia (China, Korea) . Six studies investigated patients with stages I‐IV, four with stages I‐III, two with stage III, one with stages II‐III, one with stage IV cancer .…”

Section: Resultsmentioning

confidence: 99%

“…Eight studies were conducted in Europe (United Kingdom, Denmark, Netherland, Germany), four in North America, and two in Asia (China, Korea) . Six studies investigated patients with stages I‐IV, four with stages I‐III, two with stage III, one with stages II‐III, one with stage IV cancer . One study only included patients with rectum cancer, four studies only included patients with colon cancer, while the remaining nine studies included patients with both colon cancer and rectum cancer .…”

Section: Resultsmentioning

confidence: 99%

“…Six studies investigated patients with stages I‐IV, four with stages I‐III, two with stage III, one with stages II‐III, one with stage IV cancer . One study only included patients with rectum cancer, four studies only included patients with colon cancer, while the remaining nine studies included patients with both colon cancer and rectum cancer . The methodological quality of all included case‐control and cohort studies was summarized (Table ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis

Ding

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) remains one of the most common types of cancer and a leading cause of death worldwide. Previous studies indicated that statins may have a potential protective effect on CRC. Methods We conducted this meta‐analysis to systematically assess the overall and cancer‐specific survival benefit of statin uses on CRC patients. Related references were identified through PubMed, the Cochrane Library, Web of Science, EMBASE, and SCOPUS from inception to August 2017. Adjusted hazard ratios (HRs) were adopted to calculate summary hazard ratios (HRs) with 95% confidence intervals (95% CIs), using a random‐effects model. Results Total fourteen studies involving 130 994 patients were included in this meta‐analysis. Six studies reported the association between pre‐diagnosis statin uses and CRC mortality, while 11 studies investigated mortality in patients using statins after CRC diagnosis. For pre‐diagnosis statin uses, the pooled HR of all‐cause mortality (ACM) was 0.85 (95% CI, 0.79‐0.92) and the pooled HR of cancer‐specific mortality (CSM) was 0.82 (95% CI, 0.79‐0.86). In terms of post‐diagnosis statin uses, the pooled HR of ACM was 0.86 (95% CI, 0.76‐0.98), and the pooled HR of CSM was 0.79 (95% CI, 0.70‐0.89). For post‐diagnosis statin uses, there is no difference in ACM when stratified by KRAS gene (KRAS) mutation status. Results of ACM and CSM did not markedly alter in other subgroup analyses. Conclusion Our meta‐analysis demonstrates that both pre‐diagnosis and post‐diagnosis statin uses are associated with reduced ACM and CSM for CRC patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis

Ding

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Four ‐ μm sections from each TMA block were stained immunohistochemically for CD3 and p53. p53 IHC was performed on a Leica BondMax using the DO‐7 antibody clone to p53 (Dako UK Ltd, Ely, UK; ER1‐30 min polymer kit detection) and CD3 IHC was performed on a Ventana BenchMark using the antibody clone 2GV6 (Ventana, Tucson, AZ, USA; CC1 32 min, Optiview detection), as described previously …”

Section: Methodsmentioning

confidence: 99%

Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…This arises from the nature of staining multiple cell populations (tumor and immune) and the distinction between tumor and immune cell staining being difficult due to a patchy pattern of staining [100]. Several studies have illustrated the potential of QuPath in TMA biomarker scoring [99, 101, 102], and it is also currently actively utilized by researchers to analyze mIHC/IF samples in the study of cancer immunotherapy [103]. As a whole, QuPath is still a work in progress, has only become publicly available in 2016 and is now being constantly updated with new features by its owner, P. Bankhead.…”

Section: Brightfield‐based Mihc/ifmentioning

confidence: 99%

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Tan

Nerurkar

Cai

et al. 2020

Cancer Communications

439

318

View full text Add to dashboard Cite

Conventional immunohistochemistry (IHC) is a widely used diagnostic technique in tissue pathology. However, this technique is associated with a number of limitations, including high inter-observer variability and the capacity to label only one marker per tissue section. This review details various highly multiplexed techniques that have emerged to circumvent these constraints, allowing simultaneous detection of multiple markers on a single tissue section and the comprehensive study of cell composition, cellular functional and cell-cell interactions. Among these techniques, multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF) has emerged to be particularly promising. mIHC/IF provides high-throughput multiplex staining and standardized quantitative analysis for highly reproducible, efficient and cost-effective tissue studies. This technique has immediate potential for translational research and clinical practice, particularly in the era of cancer immunotherapy.

show abstract

Statin use, Candidate Mevalonate Pathway Biomarkers, and Colon Cancer Survival in a Population-Based Cohort Study

Cited by 16 publications

References 27 publications

Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis

Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis

Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Contact Info

Product

Resources

About